학술논문
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
Document Type
Article
Author
Source
In: The Lancet . (The Lancet, 21 October 2023, 402(10411):1423-1433)
Subject
Language
English
ISSN
1474547X
01406736
01406736